Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05154994
Title Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma (RESOLVE)
Acronym RESOLVE
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors University of Utah
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST